Medindia

X

Legacy Hosts Discussion on New Studies That Show an FDA Menthol Ban Would Benefit Public Health, Garner Broad Public Support

Wednesday, May 11, 2011 General News J E 4
Advertisement

WHAT: New research to be released on May 12, 2011 in the American Journal of Public Health contains several studies specific to the negative health effects of menthol cigarettes on African American smokers. This research includes information on public attitudes regarding the elimination of menthol as a flavoring from the U.S. market as well as strong new scientific evidence in favor of the complete removal of menthol tobacco products from the marketplace – an action now being weighed by the U.S. Food and Drug Administration (FDA).

(Logo: http://photos.prnewswire.com/prnh/20101101/DC86294LOGO)

WHY: Menthol is the only tobacco flavor that has not been banned by the FDA since the agency acquired regulatory authority over tobacco products in 2009. Meanwhile, research shows that for decades, the tobacco industry has heavily marketed menthol cigarettes to minorities, and as a result, the menthol smoking rates among these communities are disproportionately high; 80 percent of African Americans who smoke, smoke menthol cigarettes. The complete removal of menthol tobacco products from the marketplace would save hundreds of thousands of lives.

WHO:

  • Dr. Louis Sullivan, Former U.S. Secretary of Health and Human Services
  • Georges C. Benjamin, MD, Executive Director, American Public Health Association
  • Aisha C. Moodie-Mills, Advisor, LGBT Policy & Racial Justice, Center for American Progress
  • Cheryl G. Healton, Dr. PH, president and CEO, Legacy®
  • Jonathan Klein, MD, MPH, Associate Executive Director, American Academy of Pediatrics and Executive Director, The Julius B. Richmond Center for Excellence
  • David Abrams, PhD, Executive Director, The Schroeder Institute for Tobacco Research and Policy Studies at Legacy®

WHEN: Thursday, May 12, 2010 at 9:30 a.m. EDT

WHERE: National Press Club, The Fourth Estate,

529 14th Street Northwest, Washington D.C., 20045

Legacy is dedicated to building a world where young people reject tobacco and anyone can quit. Located in Washington, D.C., the national public health organization helps American live longer, healthier lives. Legacy develops programs that address the health effects of tobacco use, especially among vulnerable populations disproportionately affected by the toll of tobacco, through grants, technical assistance and training, partnerships, youth activism, and counter-marketing and grassroots marketing campaigns. The foundation's programs include truth®, a national youth smoking prevention campaign that has been cited as having contributed to significant declines in youth smoking; EX®, an innovative public health program designed to speak to smokers in their own language and change the way they approach quitting; and research initiatives exploring the causes, consequences and approaches to reducing tobacco use. The American Legacy Foundation was created as a result of the November 1998 Master Settlement Agreement (MSA) reached between attorneys general from 46 states, five U.S. territories and the tobacco industry. Visit http://www.legacyforhealth.org/.

Legacy is equipped with a VideoLinkReadyCam™ television studio system, providing journalists with faster, easier access to the nation's leading tobacco prevention and cessation experts. From this in-house broadcast studio, Legacy can offer immediate access to its experts to comment on breaking news, new research publications, or any news related to youth smoking prevention, adult quit smoking programs, or any issue related to smoking. The studio is connected directly to the Vyvx fiber network and is always available for live or pre-taped interviews. To arrange an interview, please contact Julia Cartwright at 202-454-5596.

Contact: Julia Cartwright

202-454-5596

jcartwright@legacyforhealth.org

/PRNewswire-USNewswire -- May 11, 2011/

SOURCE Legacy

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
The Angiogenesis Foundation Announces 2011 Antiang...
S
Aperio Partners with Definiens to Market Definiens...